Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36

计划入组 16 人 · 首次发布于 2009 年 1 月 14 日

Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects

计划入组 16 人 · 首次发布于 2009 年 1 月 14 日

Oral Administration of Peptides; Absorption From Gastrointestinal Tract

计划入组 12 人 · 首次发布于 2007 年 5 月 3 日

Oral GLP-1 agonist(Poolbeg)

Oral GLP-1 formulation (Oralead Pharma)

NN-9926

NHI-1

United States

Oral-B Laboratories

United States

Philips Oral Healthcare

United States

Eli Lilly's Orforglipron Shows Promise as Oral GLP-1 Therapy Advances

Novo Nordisk Seeks EMA Approval for First Oral GLP-1 Diabetes Treatment

Pfizer Secures $2.1 Billion Deal for YaoPharma's Oral GLP-1 Obesity Drug